“…Since many of the currently available anticancer drugs are incapable of differentiating between normal and neoplastic cells, there is a pressing need for new anticancer agents with high potency and less toxicity to noncancerous cells. Among the broad variety of synthetic quinonoid compounds, a group of donor–acceptor members derived from 2-anilino-1,4-naphoquinone and 7-anilinoisoquinoline-5,8-quinone analogues such as compounds A, B and C ( Figure 1 ), have a wide range of remarkable in vitro cytotoxic activity against a variety of cancer cell lines [ 7 , 8 , 9 , 10 , 11 ].…”